1984 Volume 75 Issue 2 Pages 255-262
Our clinical and experimental results of immunosuppressive therapy by combined use of azathioprine and mizoribine are reported.
One year graft survival rate was 75.6% in the cases of living related renal transplantation. We experienced rather frequent occurence of leukopenia as an adverse effect of immunosuppression especially in the recipients whose grafts were poorly functioning. Because mizoribine is excreted from kidney, it is necessary to reduce the dosage of mizoribine to prevent the accumulation of the drug.
Combined use of azathioprine and mizoribine inhibited PHA induced lymphocyte blastogenesis more strongly than separate use of each drug. The influence of azathioprine and mizoribine on the cell cycle progression of cultured cell line was analysed by flow cytometry. Both drugs showed similar mode of action, namely, cultured cell was accumulated to S phase. Because azathioprine and mizoribine act at different point in the synthesis of purine nucleotides, combined use of them seems to block the pathway of DNA synthesis sequentially and stronger immunosuppressive effect is expected.
